Adaptación del "Cuestionario de Evaluación de la Adhesión al Tratamiento antirretroviral" (CEAT-VIH) para su uso en Perú

  1. Tafur Valderrama, E.
  2. Ortiz, C.
  3. Alfaro, CO.
  4. García Jiménez, E. 1
  5. Faus, MJ. 1
  1. 1 Universidad de Granada
    info

    Universidad de Granada

    Granada, España

    ROR https://ror.org/04njjy449

Journal:
Ars pharmaceutica

ISSN: 2340-9894,  0004-2927

Year of publication: 2008

Volume: 49

Issue: 3

Pages: 183-198

Type: Article

DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Ars pharmaceutica

Abstract

Objective: To adapt and validate the “Assessment of Adherence to Antiretroviral Therapy Questionnary” “Cuestionario para evaluar la adhesión al tratamiento antirretroviral” (CEAT-VIH) for use in Peru, in HIV-infected patients in highly active antiretroviral therapy (HAART). Method: Understanding of the questionnaire was evaluated as well as its psychometric properties in 41 HIV-infected patients; antiretroviral therapy for at least 3 months was required. Data was obtained between December 2005 and January 2006. CEAT-VIH was carried out the day when sample for HIV viral load and CD4 cell count were taken. Reliability and validity related to two external criterions were evaluated. Results: CEAT-VIH showed appropriate reliability (α = 0,706) and adequate external criterion-related validity for CD4 cell count (r = 0,439, p < 0.005), and for HIV viral load (r = - 0,548, p < 0, 005). Conclusions: CEAT-VIH has proved to be useful to assess the level of adherence and to identify the factors affecting patient adherence to highly active antiretroviral therapy in Peru.

Bibliographic References

  • Grupo de Investigación en Atención Farmacéutica (CTS-131). Tercer Consenso de Granada sobre Problemas Relacionados con Medicamentos (PRM) y Resultados Negativos asociados a la Medicación (RNM). Ars Pharmaceutica 2007; 48(1):5-17.
  • OGE – MINSA. Situación del VIH/SIDA en el Perú. Boletín Epidemiológico Mensual Diciembre 2007. Disponible en: http://www.oge.sld.pe/vigilancia/vih/Boletin_2007/diciembre.pdf. Con acceso enero 2008.
  • Ministerio de Salud-Perú. Norma técnica para el Tratamiento Antirretroviral de Gran Actividad-TARGA en adultos infectados por el virus de la inmunodefi ciencia humana. Nt Nº124-2004-MINS/DGSP-V.01
  • Ido K. Role of pharmacists in medical team on HIV infection. Yakugaku Zasshi. 2006;126(6):409-14.
  • Mannheimer S, Friedland G, Matts J, Child C, Chesney. The Consistency of Adherence to Antiretroviral Therapy Predicts Biologic Outcomes for Human Immunodeficiency Virus–Infected Persons in Clinical Trials. Clin Infect Dis 2002; 34:1115–21.
  • Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990; 47(3): 533-543.
  • Mac Keigan L, Pathak D. Overview of health-related quality-of-life measures. Am J Hosp Pharm 1992;49:2236-2244.
  • Machuca M, Fernández-Llimós F, Faus MJ. Guía de seguimiento farmacoterapéutico. Grupo de Investigación en Atención Farmacéutica (CTS-131).Universidad de Granada. 2003.
  • Codina C, Tuset M, Ibarra O, Delgado O, Morancho O, García B, Grupo VIH de la SEFH. Evaluación de un Programa de Atención Farmacéutica dirigido a mejorar la Adherencia al Tratamiento Antirretroviral. Farm Hosp (Madrid) 2004; 28 (Supl 1):19-26
  • Sandí J, Arias L. Impacto de la inducción farmacéutica sobre la adherencia de pacientes VIH/SIDA con tratamiento antirretroviral en el Hospital San Juan de Dios (Costa Rica). Seguim Farmacoter 2003; 1(2): 43-48.
  • Foisy M. Pharmaceutical Care for HIV Patients on Directly Observed Therapy. Ann Pharmacother 2000: 38 (4): 550-556.
  • Rudorf D, Krikorian S. Adverse Effects Associated With Antiretroviral Therapy and Potential Management Strategies. J Pharm Pract 2005; 18(4): 258-277.
  • Ventura J, Alós M. Programa de atención farmacéutica a pacientes VIH con tratamiento antirretroviral: metodología y documentación. Farm Hosp (Madrid). 2004; 28.(Supl. 1): 72-79.
  • Paton N, Chapman C, Chan S, Tan K, Leo Y, Aboulhab J, Soh C. Validation of the Medical Outcomes Study HIV Health Survey as a measure of quality of life in HIV infected patients in Singapure. Int J STD & AIDS 2002;13:456-461.
  • Kitahata M, Reed SD, Dillingham PW, Van Rompaey SE, Young AA, Harrington RD, Holmes KK. Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. Int J STD AIDS. 2004 Dec;15(12):803-10.
  • Wood E, Hogg R, Yip B, Harrigan R, O’Shaughnessy M, Montaner J. The Impact of Adherence on CD4 Cell Count Responses Among HIV-Infected Patients. J Acquir Immune Defi c Syndr 2004; 35 (3): 261-268.
  • Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The Consistency of Adherence to Antiretroviral Therapy Predicts Biologic Outcomes for Human Immunodefi ciency Virus–Infected Persons in Clinical Trials. Clin Infec Dis 2002; 34:1115–21.
  • Nachega J, Hislop M, Dowdy D, Chaisson R, Regensberg L, Maartens G. Effect of NNRTI–Based HIV Therapy Adherence on HIV-1 RNA. Ann Intern Med. 2007; 146:564-573.
  • Rigueira A. Cumplimiento terapéutico: ¿Qué conocemos en España? Aten Primaria 2001;27:559-568.
  • Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG Adherence instruments. AIDS Care 2000;12(3):255-266.
  • Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti J. Adherence to highly active antirretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. SOC SCI MED 2002; 54:1481-1496.
  • Pegueró E, Zorat M, Gené J. Cumplimiento y entrevista terapéutica. Med Clin (Barc) 2001;116(sup2):52-55.
  • Bland JM, Altman DG. Cronbach’s alpha. BMJ. 1997; 314: 572.
  • Comín Bertrán E. Validación de encuestas. Aten Primaria 1990;7(5): 68-72.
  • Hyland ME. A brief guide to the selection of quality of life instrument. Health Qual Life Outcomes 2003, 1:24.
  • Wiebe S, Guyatt G, Weaver B, Matijevic S, Sidwell C. Comparative responsiveness of generic and specifi c qualityof-life instruments. J Clin Epidemiol. 2003; 56(1): 52-60.
  • Terwee CB, Dekker FW, Wiersinga WM, Prummel MF, Bossuyt PM. On assessing responsiveness of health-related quality of life instruments: Guidelines for instrument evaluation. Qual Life Res 2003; 12: 349–362.
  • Remor E. Valoración de la adhesión al tratamiento antirretroviral en pacientes VIH+. Psicothema 2002;14(3):262-267.
  • Remor E. Manual del Cuestionario para la Evaluación de la Adhesión al Tratamiento Antirretroviral (CEAT-VIH). Versión 1.0, Madrid, 2002.
  • Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Acceso: Febrero 2008.
  • Bell DJ, Kapitao Y, Sikwese R, van Oosterhout JJ, Lalloo DG. Adherence to antiretroviral therapy in patients receiving free treatment from a government hospital in Blantyre, Malawi. J Acquir Immune Defi c Syndr. 2007 Aug 15; 45(5):560-3.
  • Duong M, Piroth L, Grappin M, Forte F, Peytavin G, Buisson M, Chavanet P, Portier H. Evaluation of the Patient Medication Adherence Questionnaire as a tool for self-reported adherence assessment in HIV-infected patients on antiretroviral regimens. HIV Clin Trials. 2001 Mar-Apr; 2(2):128-35.
  • Muñoz-Moreno JA, Fumaz CR, Ferrer MJ, Tuldrà A, Rovira T, et al. Assessing self-reported adherence to HIV therapy by questionnaire: the SERAD (Self-Reported Adherence) Study. AIDS Res Hum Retroviruses. 2007; 23(10):1166-75.
  • Gallo FJ et al. Manual del Residente de Medicina Familiar y Comunitaria. Ed Barcelona, 1993. pp 733.
  • Sherr L, Lampe F, Norwood S, Leake Date H, Harding R, Johnson M, Edwards S, Fisher M, Arthur G, Zetler S, Anderson J. Adherence to antiretroviral treatment in patients with HIV in the UK: a study of complexity. AIDS Care. 2008 Apr;20(4):442-8.
  • Nilsson Schönnesson L, Diamond PM, Ross MW, Williams M, Bratt G. Baseline predictors of three types of antiretroviral therapy (ART) adherence: A 2-year follow-up. AIDS Care. 2006 May;18(4):407-14.
  • Johnson MO, Chesney MA, Goldstein RB, Remien RH, Catz S, Gore-Felton C, Charlebois E, Morin SF. Positive provider interactions, adherence self-effi cacy, and adherence to antiretroviral medications among HIV-infected adults: A mediation model. AIDS Patient Care STDS. 2006; 20(4):258-68.
  • Bimbela J. Cuidando al profesional de la salud. Habilidades Emocionales y de comunicación. Escuela andaluza de Salud publica 2005. 1ºEdición.
  • Remor E, Milner-Moskovics J, Preussler G. Adaptação brasileira do “Cuestionario para la Evaluación de la Adhesión al Tratamiento Antiretroviral” Rev Saúde Pública 2007;41(5).
  • Knobela H, Alonsob J, Casadoc J, Collazos J, Gonzalez J, Ruiz I, et al. Validation of a simplifi ed medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS 2002, 16:605-613.
Data source: Dialnet